Recognizes a protein of 55kDa, identified as CD25 (Workshop IV; Code A27). CD25 is expressed on activated T- and B-cells and activated monocytes/macrophages. With respect to lymphomas, CD25 is present on malignant cells of Hodgkin’s disease, HTLV-1+ adult T-cell leukemia, cutaneous T-cell lymphoma, and hair cell leukemia. Increased levels of soluble CD25 are observed in the leukemias/lymphomas and inflammatory/ autoimmune diseases. CD25 molecule alone appears to function as a low affinity receptor and associates with CD122 (IL-2R ļ� � chain, p75) and CD132 (common ļ� � chain) to form the high affinity IL-2 receptor complex. CD25 antibodies detect three epitope regions, A, B and C. This MAb recognizes the epitope B, which is located at residue 3-104 of CD25 and can effectively block IL-2 binding to CD25.
PHA-stimulated human lymphocytes. Human lymph nodes and tonsils.
elisa-detection
Human
desc-reactivity-1
FALSE
desc-molecular-weight-1
RUO
desc-applications-8
FACS, IF
desc-categories-1
Functional Studies (Order Ab without Azide); Optimal dilution for a specific application should be determined.
desc-cellular-localization-1
FACS0.5-1μg/million cells in 0.1mlIF0.5-1μg/ml
desc-conjugate-1
P01589
desc-constituent-1
231367
desc-description-1:{15}(Description) Description
3559
desc-involvement-in-disease-1
200μg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA; 0.05% azide. Also available WITHOUT BSA; azide at 1.0mg/ml.
desc-isotype-1:{29}(Description) Isotype
1.0mg/ml
instructions-for-use
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.